FDA warned Amish Origins over manufacturing quality failures and unapproved or misbranded OTC pain relief and lip balm products.
What happened
FDA inspected the Worland, Wyoming drug manufacturing facility from January 7 to 10, 2025 and reviewed the company's February 1, 2025 response to the Form FDA 483 (inspection observations). FDA found missing finished-product release testing, missing component identity testing including for glycerin, no executed batch records, inadequate quality unit oversight, and label claims that make the pain relief products unapproved new drugs; it also found the SPF 15 lip product missing required warnings.
What FDA found
The company released drug products without testing each batch to confirm identity, strength, purity, and freedom from objectionable microorganisms.
21 CFR 211.165(a) and 211.165(b)The company did not test each incoming component lot for identity and relied on supplier certificates of analysis without establishing that the suppliers' test results were reliable.
21 CFR 211.84(d)(1) and 211.84(d)(2)The company did not test each glycerin lot with the USP identity test that detects diethylene glycol (DEG) and ethylene glycol (EG), which can cause lethal poisoning.
21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)The company had no complete batch production and control records and no executed batch records for distributed drug products.
21 CFR 211.188The quality control unit lacked written procedures and did not effectively oversee manufacturing quality.
21 CFR 211.22The pain relief products were labeled for uses beyond FDA's allowed uses for OTC external analgesics, making them unapproved new drugs, and the SPF 15 lip product lacked required warnings, making it misbranded.
FD&C Act sections 505(a), 301(d), 502(ee), and 502(f)(2); 21 U.S.C. 355(a), 331(d), 352(ee), and 352(f)(2)
What FDA wants
FDA tells the company to correct the CGMP and labeling violations and to provide detailed corrective action plans, test methods and results, supplier qualification records, and batch records; it specifically requires DEG and EG test results within 30 calendar days.
Who should pay attention
- brands that buy or distribute OTC topical analgesics from contract manufacturers
- companies using glycerin or other high-risk drug components
- retailers and consumers of OTC pain relief and SPF lip products
This is a summary. Read the original letter on fda.gov.